You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The company also plans to submit a new drug application for avapritinib in mainland China in the first half of this year.
The trial evaluated the safety and preliminary activity of the single-agent therapy for FGFR2b-overexpressing gastric cancers.
The partnership aims to analyze the differences in the tumor microenvironments of cancer patients and use that to classify tumors and determine treatment prognosis.
Five Prime Therapeutics provided an update on the development of bemarituzumab and FPA150, and Gritstone Oncology discussed plans for its personalized immunotherapies.
In the trial that led to Ayvakit's approval, 84 percent of patients with PDGFRA exon 18 mutations saw their tumors shrink.
In the studies, the Merck immunotherapy extended survival for advanced lung cancer and stomach cancer patients with high PD-L1 expression.
The diagnostic can now be used to identify a wider range of patients with stage III or metastatic NSCLC who may benefit from first-line treatment with Keytruda.
A phylogenetic analysis that included multiple samples per patient suggests overlapping driver mutations make their way into multiple metastases in each patient.
Physicians can now use the Dako PD-L1 IHC 22C3 pharmDx assay to identify urothelial carcinoma patients who may benefit from the anti-PD1 immunotherapy.
An international team of researchers also suggested that MUC16 mutations could identify patients who might benefit from immunotherapy treatment.